Sanofi Pasteur has submitted Hexaxim vaccine to EMA for approval in Europe - 21-Oct-2012

The Hexaxim vaccine (DTaP-IPV-Hib-HepB) has been submitted by Sanofi Pasteur MSD to the EMA for approval to licence within the European Union. Upon approval the company says it will commercialise it in its European territories under its own brand name. The new hexavalent vaccine, developed by Sanofi Pasteur, is the only fully liquid, ready to use 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

Related News

Related Infectious Diseases Information

Related Infectious Diseases Drugs

Back to top

Latest News

10 May 2015
23 May 2013
22 May 2013